Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human.

ABSTRACT:

Background

Inflammation has been associated with progression and complications of chronic heart failure (HF) but no effective therapy has yet been identified to treat this dysregulated immunologic state. The selective cytopheretic device (SCD) provides extracorporeal autologous cell processing to lessen the burden of inflammatory activity of circulating leukocytes of the innate immunologic system.

Aim

The objective of this study was to evaluate the effects of the SCD as an extracorporeal immunomodulatory device on the immune dysregulated state of HF. HF.

Methods and results

SCD treatment in a canine model of systolic HF or HF with reduced ejection fraction (HFrEF) diminished leukocyte inflammatory activity and enhanced cardiac performance as measured by left ventricul

SUBMITTER: Humes HD 

PROVIDER: S-EPMC10079025 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature